Pengxia Qu, Shuang Yang, Yaowen Guo, Tiantao Jing, Wan Zhang, Yuanbin Li
{"title":"The Relationship Between Thyroid Function Status and Serum Uric Acid Levels Based on a Restricted Cubic Spline Model: A Cross-Sectional Study.","authors":"Pengxia Qu, Shuang Yang, Yaowen Guo, Tiantao Jing, Wan Zhang, Yuanbin Li","doi":"10.2147/RMHP.S536398","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>To date, no comprehensive studies have examined the relationship between various thyroid function statuses and thyroid hormone levels with uric acid levels. This study aims to analyze the correlation between thyroid disease and hyperuricemia.</p><p><strong>Patients and methods: </strong>Data from individuals undergoing health screenings in the Taiyuan area were collected. The data were categorized by thyroid disease type, thyroid function indices (FT4, FT3, and TSH), and serum uric acid (SUA) levels, followed by statistical analysis.</p><p><strong>Results: </strong>The analysis indicated that the prevalence rates were as follows: clinical hyperthyroidism (CHyper) at 0.9%, subclinical hyperthyroidism (SCHyper) at 0.7%, clinical hypothyroidism (CHypo) at 0.8%, subclinical hypothyroidism (SCHypo) at 13.7%, and hyperuricemia at 16.9%. Further analysis revealed that the prevalence of hyperuricemia increased with higher FT4 and FT3 levels but decreased with lower TSH levels. However, logistic regression analysis showed that after adjusting for covariates, thyroid disease status, including CHyper, SCHyper, CHypo, and SCHypo, was not significantly correlated with hyperuricemia. Among the thyroid function indices, only FT4 had a statistically significant effect on the risk of hyperuricemia (OR 1.028, 95% CI 1.011-1.045). Additionally, the restricted cubic spline (RCS) was employed to assess the dose-response relationship between thyroid function indicators (FT4, FT3, and TSH) within the normal reference range and the risk of hyperuricemia. The FT4 level exhibited a positive relationship with the risk of hyperuricemia (nonlinear test χ<sup>2</sup> was 0.26, <i>P > 0.05</i>). When FT4 exceeded 16.85 pmol/L, higher levels of FT4 became a risk factor for hyperuricemia.</p><p><strong>Conclusion: </strong>Thyroid disease status does not significantly affect hyperuricemia. However, within the normal range, the FT4 level demonstrates a positive dose-response relationship with the risk of hyperuricemia.</p>","PeriodicalId":56009,"journal":{"name":"Risk Management and Healthcare Policy","volume":"18 ","pages":"3199-3208"},"PeriodicalIF":2.0000,"publicationDate":"2025-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12476191/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Risk Management and Healthcare Policy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2147/RMHP.S536398","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"HEALTH CARE SCIENCES & SERVICES","Score":null,"Total":0}
引用次数: 0
Abstract
Purpose: To date, no comprehensive studies have examined the relationship between various thyroid function statuses and thyroid hormone levels with uric acid levels. This study aims to analyze the correlation between thyroid disease and hyperuricemia.
Patients and methods: Data from individuals undergoing health screenings in the Taiyuan area were collected. The data were categorized by thyroid disease type, thyroid function indices (FT4, FT3, and TSH), and serum uric acid (SUA) levels, followed by statistical analysis.
Results: The analysis indicated that the prevalence rates were as follows: clinical hyperthyroidism (CHyper) at 0.9%, subclinical hyperthyroidism (SCHyper) at 0.7%, clinical hypothyroidism (CHypo) at 0.8%, subclinical hypothyroidism (SCHypo) at 13.7%, and hyperuricemia at 16.9%. Further analysis revealed that the prevalence of hyperuricemia increased with higher FT4 and FT3 levels but decreased with lower TSH levels. However, logistic regression analysis showed that after adjusting for covariates, thyroid disease status, including CHyper, SCHyper, CHypo, and SCHypo, was not significantly correlated with hyperuricemia. Among the thyroid function indices, only FT4 had a statistically significant effect on the risk of hyperuricemia (OR 1.028, 95% CI 1.011-1.045). Additionally, the restricted cubic spline (RCS) was employed to assess the dose-response relationship between thyroid function indicators (FT4, FT3, and TSH) within the normal reference range and the risk of hyperuricemia. The FT4 level exhibited a positive relationship with the risk of hyperuricemia (nonlinear test χ2 was 0.26, P > 0.05). When FT4 exceeded 16.85 pmol/L, higher levels of FT4 became a risk factor for hyperuricemia.
Conclusion: Thyroid disease status does not significantly affect hyperuricemia. However, within the normal range, the FT4 level demonstrates a positive dose-response relationship with the risk of hyperuricemia.
期刊介绍:
Risk Management and Healthcare Policy is an international, peer-reviewed, open access journal focusing on all aspects of public health, policy and preventative measures to promote good health and improve morbidity and mortality in the population. Specific topics covered in the journal include:
Public and community health
Policy and law
Preventative and predictive healthcare
Risk and hazard management
Epidemiology, detection and screening
Lifestyle and diet modification
Vaccination and disease transmission/modification programs
Health and safety and occupational health
Healthcare services provision
Health literacy and education
Advertising and promotion of health issues
Health economic evaluations and resource management
Risk Management and Healthcare Policy focuses on human interventional and observational research. The journal welcomes submitted papers covering original research, clinical and epidemiological studies, reviews and evaluations, guidelines, expert opinion and commentary, and extended reports. Case reports will only be considered if they make a valuable and original contribution to the literature. The journal does not accept study protocols, animal-based or cell line-based studies.